Literature DB >> 22265415

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

William A Freed-Pastor1, Hideaki Mizuno, Xi Zhao, Anita Langerød, Sung-Hwan Moon, Ruth Rodriguez-Barrueco, Anthony Barsotti, Agustin Chicas, Wencheng Li, Alla Polotskaia, Mina J Bissell, Timothy F Osborne, Bin Tian, Scott W Lowe, Jose M Silva, Anne-Lise Børresen-Dale, Arnold J Levine, Jill Bargonetti, Carol Prives.   

Abstract

p53 is a frequent target for mutation in human tumors, and mutant p53 proteins can actively contribute to tumorigenesis. We employed a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids reminiscent of acinar structures found in vivo, whereas breast cancer cells display highly disorganized morphology. We found that mutant p53 depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like morphology. Genome-wide expression analysis identified the mevalonate pathway as significantly upregulated by mutant p53. Statins and sterol biosynthesis intermediates reveal that this pathway is both necessary and sufficient for the phenotypic effects of mutant p53 on breast tissue architecture. Mutant p53 associates with sterol gene promoters at least partly via SREBP transcription factors. Finally, p53 mutation correlates with highly expressed sterol biosynthesis genes in human breast tumors. These findings implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265415      PMCID: PMC3511889          DOI: 10.1016/j.cell.2011.12.017

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  58 in total

Review 1.  Transcriptional regulation by p53: one protein, many possibilities.

Authors:  O Laptenko; C Prives
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

2.  Mutant p53 gain of function: the NF-Y connection.

Authors:  Melissa J Peart; Carol Prives
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

Review 3.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Authors:  A Petitjean; M I W Achatz; A L Borresen-Dale; P Hainaut; M Olivier
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

4.  Breast cancer growth prevention by statins.

Authors:  Michael J Campbell; Laura J Esserman; Yamei Zhou; Mark Shoemaker; Margaret Lobo; Elizabeth Borman; Frederick Baehner; Anjali S Kumar; Kelly Adduci; Corina Marx; Emanuel F Petricoin; Lance A Liotta; Mary Winters; Stephen Benz; Christopher C Benz
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 5.  Statins and risk of cancer: a systematic review and metaanalysis.

Authors:  Danielle R L Browning; Richard M Martin
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

6.  Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK.

Authors:  Meral Koyuturk; Melike Ersoz; Nedret Altiok
Journal:  Cancer Lett       Date:  2006-11-27       Impact factor: 8.679

7.  Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes.

Authors:  M J Bissell; P A Kenny; D C Radisky
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

8.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Authors:  Magali Olivier; Anita Langerød; Patrizia Carrieri; Jonas Bergh; Sigrid Klaar; Jorunn Eyfjord; Charles Theillet; Carmen Rodriguez; Rosette Lidereau; Ivan Bièche; Jennifer Varley; Yves Bignon; Nancy Uhrhammer; Robert Winqvist; Arja Jukkola-Vuorinen; Dieter Niederacher; Shunsuke Kato; Chikashi Ishioka; Pierre Hainaut; Anne-Lise Børresen-Dale
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

9.  Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.

Authors:  Anjali S Kumar; Christopher C Benz; Veronica Shim; Christina A Minami; Dan H Moore; Laura J Esserman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05-07       Impact factor: 4.254

10.  Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes.

Authors:  Brian D Reed; Alexandra E Charos; Anna M Szekely; Sherman M Weissman; Michael Snyder
Journal:  PLoS Genet       Date:  2008-07-25       Impact factor: 5.917

View more
  398 in total

1.  Oncogenic morphs of p53.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2012-02-24       Impact factor: 60.716

2.  Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition.

Authors:  Yanhong Zhang; Wensheng Yan; Yong Sam Jung; Xinbin Chen
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

3.  Polyoxometalates functionalized by bisphosphonate ligands: synthesis, structural, magnetic, and spectroscopic characterizations and activity on tumor cell lines.

Authors:  Hani El Moll; Wei Zhu; Eric Oldfield; L Marleny Rodriguez-Albelo; Pierre Mialane; Jérôme Marrot; Neus Vila; Israel Martyr Mbomekallé; Eric Rivière; Carole Duboc; Anne Dolbecq
Journal:  Inorg Chem       Date:  2012-06-22       Impact factor: 5.165

4.  Statins and Breast Cancer: Future Directions in Chemoprevention.

Authors:  Cesar A Santa-Maria; Vered Stearns
Journal:  Curr Breast Cancer Rep       Date:  2013-09-01

Review 5.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

6.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

7.  Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies.

Authors:  Elizabeth J Pereira; Joseph S Burns; Christina Y Lee; Taylor Marohl; Delia Calderon; Lixin Wang; Kristen A Atkins; Chun-Chao Wang; Kevin A Janes
Journal:  Sci Signal       Date:  2020-04-14       Impact factor: 8.192

8.  Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.

Authors:  Hyeon Jeong Lee; Jie Li; Renee E Vickman; Junjie Li; Rui Liu; Abigail C Durkes; Bennett D Elzey; Shuhua Yue; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

Review 9.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

Review 10.  The Role of Cholesterol in Cancer.

Authors:  Omer F Kuzu; Mohammad A Noory; Gavin P Robertson
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.